News & Analysis on Clinical Trial Services & Contract Research And Development
Researchers at the University of Rochester and StemCapture have unveiled a new device technology that makes it possible to harvest stem cells from the blood, bypassing the controversial use of stem cells sourced from embryos.
Millipore has introduced a new disposable product - NovaSeal - that ties in with a shift in the bioprocess manufacturing market to the use of disposable assemblies to shorten production cycles for drugs.
UK-based SkyePharma has found a buyer for its ailing injectable business in a deal that could be worth over $82m (€63m).
Despite the many challenges facing the pharma industry, drug developers should be optimistic, and one of the reasons is the increasing reliance on global outsourcing to speed development and reduce costs, says new report.
Radiofrequency identification (RFID) tag adoption will be hampered by a lack of a skilled labour force that is adequately trained to handle this new technology, research reveals.
BN ImmunoTherapeutics, the US subsidiary of Denmark's Bavarian Nordic, has started clinical trials of MVA-BN-HER2, a new vaccine targeting breast cancer.
The use of virtual patients to simulate clinical trials on computers can forecast their results, potentially optimising drug development and saving the pharmaceutical industry billions.
Caliper Life Sciences is making the most of its recent acquisitions by launching a new drug discovery and development services business - created from the integration of two companies it recently bought - in a bid to offer a "in vitro-in vivo bridge"...
Although US spending on healthcare rose by 6.9 per cent in 2005, taking it to almost $2 trillion (€1.5 trillion), it's the smallest increase since 1999, down from 7.2 per cent in 2004 and 8.1 per cent in 2003.
Helix BioPharma and BioVectra have signed a deal for the manufacture of Helix's new lung cancer drug for clinical trials - a move that strengthens the already existing relationship between the two Canadian firms.
Several discontinued drug candidates that target the central nervous system (CNS) have been given a second chance for success after Synosis Therapeutics bought them off Roche.
Cellexus has introduced a technology - CellMaker Lite - that satisfies the appetite for disposable bioreactors, grows bacterial and mammalian cells efficiently and cuts production costs.
Ness Technologies is smiling after Quintiles awarded a multi-million dollar outsourcing contract to the Indian IT services firm.
Genentech has shown their faith in a blood cancer drug development programme by licensing just one compound for up $800m (€615m), highlighting the willingness of large pharmaceutical companies to pay large sums for even a single drug candidate.